Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 57 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/8/2007 First Published: 9/1/1994


1.		Phase III Randomized Study of Adjuvant Tamoxifen With or Without Ovarian Suppression and/or Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Premenopausal Women With Stage I-IIIA, Unilateral, Invasive Breast Cancer (Summary Last Modified 12/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				70 and under								SCTN-BR9401 EU-94002, UKCCCR-ABC/BR9401, NCT00002580

Last Modified: 5/31/2007


2.		Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression, and/or Chemotherapy in Women With Stage I, II, and IIIA Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified								NCRI-ABC CRC-TU-BR3010, SCTN-BR9401/BR9402, YRCO-ABC, EU-94029, UKCCCR-ABC, NCT00002582

Last Modified: 9/6/2006


3.		Phase III Randomized Study of Adjuvant Tamoxifen with vs without Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer 3 cm or Less in Diameter (Summary Last Modified 03/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				premenopausal				NCI				E-3193 CLB-9494, NCCTG-933252, SWOG-9347, INT-0142, E3193

Last Modified: 7/20/2007 First Published: 11/1/1994


4.		Phase III Randomized Study of Radiotherapy With or Without Neoadjuvant Flutamide Plus Goserelin or Leuprolide in Patients With Good Prognosis, Locally Confined Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				RTOG-9408 NCT00002597, RTOG-94-08

Last Modified: 1/4/2007 First Published: 3/1/1995


5.		Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Under 80				NCI				CAN-NCIC-PR3 CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3

Last Modified: 5/28/2008


6.		Phase III Randomized Study of Radical Prostatectomy with vs without Neoadjuvant Hormone Therapy Using Leuprolide or Goserelin and Flutamide or Bicalutamide for Stage I/II Prostate Cancer (Summary Last Modified 08/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to 70				NCI				SWOG-S9615 SWOG-9615, S9615

Last Modified: 5/10/2007 First Published: 12/1/1996


7.		Phase III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With or Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				E-8892 CLB-E8892, SWOG-E8892, NCT00002881, E8892

Last Modified: 11/1/1998


8.		Phase III Study of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate (Summary Last Modified 11/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Not specified				NCI				RTOG-9608 RTOG-96-08

Last Modified: 5/22/2006 First Published: 1/1/1999


9.		Phase III Randomized Adjuvant Study of Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk of Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				MDA-ID-97077 E-97077, NCI-T97-0069, NCT00003645, T97-0069

Last Modified: 2/23/2007 First Published: 1/1/1999


10.		Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				CAN-NCIC-PR7 SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute